Cidara Gross Profit from 2010 to 2024

CDTX Stock

USD 19.59 0.90 4.82%

Cidara Therapeutics Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2024. Gross Profit is the profit Cidara Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2013-12-31

Previous Quarter

6.9 M

Current Value

245 K

Quarterly Volatility

9.3 M

Yuan Drop

Covid

Check Cidara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cidara Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 210.4 K, Selling General Administrative of 14 M or Other Operating Expenses of 63.2 M, as well as many indicators such as Price To Sales Ratio of 1.03, Dividend Yield of 0.0 or Days Sales Outstanding of 111. Cidara financial statements analysis is a perfect complement when working with Cidara Therapeutics Valuation or Volatility modules.

Check out the analysis of Cidara Therapeutics Correlation against competitors.

For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.

Latest Cidara Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Cidara Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of Cidara Therapeutics minus its cost of goods sold. It is profit before Cidara Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Cidara Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cidara Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (11.23 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Cidara Gross Profit Regression Statistics

	Arithmetic Mean	4,020,473
	Geometric Mean	0.00
	Coefficient Of Variation	998.71
	Mean Deviation	30,088,161
	Median	(1,607,000)
	Standard Deviation	40,152,719
	Sample Variance	1612.2T
	Range	121.5M
	R-Value	0.45
	Mean Square Error	1388.7T
	R-Squared	0.20
	Significance	0.09
	Slope	4,016,924
	Total Sum of Squares	22571.4T

Cidara Gross Profit History

	2024	65.5 M
	2023	62.4 M
	2022	64.3 M
	2021	49.6 M
	2020	-56 M
	2019	-25.5 M
	2018	-49.1 M

Other Fundumenentals of Cidara Therapeutics

Gross Profit Margin

Cidara Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Total Liab	Total Current Assets	Net Tangible Assets	Common Stock	Property Plant Equipment	Capital Surpluse	Net Receivables	Long Term Debt Total	Short Long Term Debt	Short Term Debt	Net Invested Capital	Net Working Capital	Current Deferred Revenue	Capital Stock
Total Assets		0.73	-0.94	-0.47	0.79	0.47	0.43	1.0	0.83	0.34	0.24	0.37	0.26	-0.45	-0.3	-0.24	-0.23	-0.26	0.23	0.2
Total Stockholder Equity	0.73		-0.9	0.23	0.41	0.11	-0.3	0.75	0.97	-0.37	0.48	-0.28	-0.43	0.16	0.29	0.26	0.47	0.45	-0.44	-0.43
Net Debt	-0.94	-0.9		0.18	-0.62	-0.32	-0.12	-0.95	-0.95	-0.05	-0.44	-0.11	0.07	0.18	0.08	0.07	-0.07	-0.06	0.06	0.03
Retained Earnings	-0.47	0.23	0.18		-0.58	-0.55	-0.97	-0.44	0.06	-0.94	0.28	-0.95	-0.85	0.92	0.79	0.69	0.92	0.92	-0.85	-0.83
Accounts Payable	0.79	0.41	-0.62	-0.58		0.52	0.57	0.78	0.52	0.42	-0.18	0.51	0.55	-0.58	-0.34	-0.26	-0.43	-0.5	0.47	0.29
Long Term Debt	0.47	0.11	-0.32	-0.55	0.52		0.51	0.46	0.13	0.45	-0.15	0.54	0.36	-0.55	-0.39	-0.36	-0.39	-0.4	0.39	0.35
Total Liab	0.43	-0.3	-0.12	-0.97	0.57	0.51		0.4	-0.12	0.97	-0.3	0.89	0.93	-0.85	-0.81	-0.68	-0.95	-0.96	0.9	0.86
Total Current Assets	1.0	0.75	-0.95	-0.44	0.78	0.46	0.4		0.85	0.31	0.26	0.34	0.23	-0.43	-0.28	-0.22	-0.2	-0.23	0.19	0.17
Net Tangible Assets	0.83	0.97	-0.95	0.06	0.52	0.13	-0.12	0.85		-0.2	0.43	-0.11	-0.27	-0.01	0.15	0.13	0.31	0.28	-0.29	-0.29
Common Stock	0.34	-0.37	-0.05	-0.94	0.42	0.45	0.97	0.31	-0.2		-0.26	0.87	0.89	-0.8	-0.84	-0.73	-0.95	-0.93	0.9	0.92
Property Plant Equipment	0.24	0.48	-0.44	0.28	-0.18	-0.15	-0.3	0.26	0.43	-0.26		-0.21	-0.48	0.32	0.09	0.14	0.4	0.51	-0.35	-0.14
Capital Surpluse	0.37	-0.28	-0.11	-0.95	0.51	0.54	0.89	0.34	-0.11	0.87	-0.21		0.76	-0.87	-0.73	-0.68	-0.87	-0.85	0.88	0.86
Net Receivables	0.26	-0.43	0.07	-0.85	0.55	0.36	0.93	0.23	-0.27	0.89	-0.48	0.76		-0.74	-0.67	-0.51	-0.92	-0.97	0.9	0.76
Long Term Debt Total	-0.45	0.16	0.18	0.92	-0.58	-0.55	-0.85	-0.43	-0.01	-0.8	0.32	-0.87	-0.74		0.75	0.66	0.75	0.79	-0.71	-0.65
Short Long Term Debt	-0.3	0.29	0.08	0.79	-0.34	-0.39	-0.81	-0.28	0.15	-0.84	0.09	-0.73	-0.67	0.75		0.95	0.79	0.72	-0.73	-0.82
Short Term Debt	-0.24	0.26	0.07	0.69	-0.26	-0.36	-0.68	-0.22	0.13	-0.73	0.14	-0.68	-0.51	0.66	0.95		0.7	0.61	-0.67	-0.79
Net Invested Capital	-0.23	0.47	-0.07	0.92	-0.43	-0.39	-0.95	-0.2	0.31	-0.95	0.4	-0.87	-0.92	0.75	0.79	0.7		0.98	-0.92	-0.89
Net Working Capital	-0.26	0.45	-0.06	0.92	-0.5	-0.4	-0.96	-0.23	0.28	-0.93	0.51	-0.85	-0.97	0.79	0.72	0.61	0.98		-0.92	-0.83
Current Deferred Revenue	0.23	-0.44	0.06	-0.85	0.47	0.39	0.9	0.19	-0.29	0.9	-0.35	0.88	0.9	-0.71	-0.73	-0.67	-0.92	-0.92		0.93
Capital Stock	0.2	-0.43	0.03	-0.83	0.29	0.35	0.86	0.17	-0.29	0.92	-0.14	0.86	0.76	-0.65	-0.82	-0.79	-0.89	-0.83	0.93

Click cells to compare fundamentals

About Cidara Therapeutics Financial Statements

Cidara Therapeutics investors use historical fundamental indicators, such as Cidara Therapeutics' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cidara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	62.4 M	65.5 M
Gross Profit Margin	0.98	1.02

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Cidara Stock Analysis

When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC